IP Library Granted Patent US 12,667,592
Granted Patent B2
US 12,667,592 · App. 17/836,475 · Granted Jun 30, 2026

Compositions for restoring gene expression in neuropsychiatric or neurodegenerative disorders

Inventors: Hyman Morris Schipper (Vaudreuil-Dorion, CA); Marisa Emily Cressatti (Vaudreuil-Dorion, CA); Wei Song (Vaudreuil-Dorion, CA); Carmela Galindez (Vaudreuil-Dorion, CA); Ayda Tavitian (Vaudreuil-Dorion, CA); Adrienne Liberman (Vaudreuil-Dorion, CA); Daniel A. Linseman (Littleton, CO)
Assignee: IMMUNOTEC INC.
A61K35/20A61P25/18A61P25/28G01N2800/28G01N2800/30Y02A50/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,667,592
App. No.
17/836,475
Filed
Jun 9, 2022
Granted
Jun 30, 2026
Kind
B2
Art Unit
1675
USPC
424/535
Abstract

Methods for increasing reelin (RELN) levels in the brain of a subject in need thereof, as well as compositions for use in such methods, are provided. In addition, methods and compositions are described herein which may be used in the treatment of neuropsychiatric or neurodegenerative disorders, such as schizophrenia and Alzheimer's disease (AD). Compositions described herein may comprise whey protein isolate and/or whey protein concentrate, a source of the glutathione precursor cysteine. The provided methods and compositions are not limited to increasing RELN levels, and may be used to correct a number of other neurological disregulations or abnormalities occurring in a subject in need thereof.

Claims (8)

1 . A method for increasing reelin (RELN) levels in the prefrontal cortex (PFC) of a brain of a subject with schizophrenia, said method comprising:

a) performing a biopsy of the PFC of said subject;

determining the initial RELN level in the PFC from said biopsy; and

b) administering a composition comprising whey protein concentrate and/or whey protein isolate to said subject for 4-6 weeks;

performing a biopsy of the PFC of said subject;

determining RELN level in the PFC from said biopsy;

wherein the measured RELN level from b) is greater than the measured initial RELN level from a).

2 . The method of claim 1 , wherein the whey protein isolate or whey protein concentrate is undenatured whey protein isolate or whey protein concentrate.

Continuity (3)
Continuation 16335914
Provisional Application 62398892 · Sep 23, 2016
Related Publication 20230029577A1 · Feb 2, 2023
References Cited (18)
US 8017147B2 · Mazed et al. · 2011 [cited by applicant]
US 10052359B2 · Ano · 2018 [cited by examiner]
US 10398729B2 · Russell · 2019 [cited by applicant]
US 20130209580A1 · Russell · 2013 [cited by applicant]
Kaplan et al., Am J Clin Nutr, 2001, 74:687-93. [cited by examiner]
Camfield et al., British J Nutrition, 2011, 106: 159-74. [cited by examiner]
Morris et al., Whey processing, Functionality and Health Benefits, 2008, Wiley&Sons, 285-343. [cited by examiner]
Crichton et al., Int Dairy J, 2012, 22:15-23. [cited by examiner]
Office Action issued Nov. 2, 2023 in corresponding Canadian Patent Application No. 3,038,048. [cited by applicant]
Ross et al., “Immunocal® and Preservation of Glutathione as a Novel Neuroprotective Strategy for Degenerative Disorders of the Nervous System”, Recent Patents on CNS Drug Discovery, 2012, vol. 7, No. 3, pp. 230-235. [cited by applicant]
Bošković et al., “Oxidative Stress in Schizophrenia”, Current Neuropharmacology, 2011, vol. 9, pp. 301-312. [cited by applicant]
Herring et al., “Reelin Depletion is an Early Phenomenon of Alzheimer's Pathology”, Journal of Alzheimer's Disease, 2012, vol. 30, No. 4, pp. 963-979. [cited by applicant]
International Search Report and Written Opinion of the International Searching Authority, issued Dec. 1, 2017 in corresponding International Patent Application No. PCT/US2017/052269. [cited by applicant]
Ross et al., “Immunocal® and Preservation of Glutathione as a Novel Neuroprotective Strategy for Degenerative Disorders of the Nervous System”, Recent Patents on CNS Drug Discovery, 7(3): 230-235 (2012). [cited by applicant]
Ross et al., “A Cystine-Rich Whey Supplement (Immunocal®) Delays Disease Onset and Prevents Spinal Cord Glutathione Depletion in the hSOD1 [cited by applicant]
Rice et al., “Role of the Reelin Signaling Pathway in Central Nervous System Development”, Annu. Rev. Neurosci., 24: 1005-1039 (2001). [cited by applicant]
The Australian J. Dietary Technology, 2009, 64(1):117-21. [cited by applicant]
British J. Nutrition, 2011, 106:159-74. [cited by applicant]